📊 BLFS Key Takeaways
Is Biolife Solutions Inc. (BLFS) a Good Investment?
BioLife Solutions demonstrates strong revenue growth of 28.9% YoY with excellent gross margins of 64.6%, indicating pricing power and operational efficiency in its core products. However, the company remains unprofitable with negative operating margins of -17.3% and operating losses of $16.6M, suggesting R&D or commercialization expenses are outpacing revenue growth, though improving net losses YoY provide some encouragement.
BioLife Solutions shows strong fundamental momentum with 28.9% revenue growth, high 64.6% gross margins, and positive free cash flow, indicating that growth is translating into real cash generation. The balance sheet is exceptionally strong with high liquidity, minimal leverage, and substantial equity support, which reduces financial risk while management works toward sustained operating profitability. The main constraint is that the business is still posting operating losses, so the case depends on continued margin improvement and disciplined cost control.
Why Buy Biolife Solutions Inc. Stock? BLFS Key Strengths
- Strong revenue growth of 28.9% YoY indicates healthy market demand and successful commercial execution
- Excellent gross margin of 64.6% demonstrates strong pricing power and cost management of core products
- Fortress balance sheet with minimal debt (0.01x leverage), $33M cash, and exceptional liquidity ratios (5.94x current, 4.63x quick)
- Positive free cash flow of $10.6M (11.1% FCF margin) despite net losses shows underlying business generating cash
- Net loss improvement of 77.2% YoY and EPS improvement of 77.3% suggests trajectory toward profitability
- Strong top-line growth supported by positive operating and free cash flow
- High gross margin profile suggests attractive unit economics and pricing power
- Very strong balance sheet with high liquidity and negligible debt
BLFS Stock Risks: Biolife Solutions Inc. Investment Risks
- Significant operating loss of $16.6M with -17.3% operating margin indicates company is not yet at scale profitability
- Operating cash flow of $20.1M only marginally exceeds capex of $9.5M, leaving limited buffer for growth investments
- Negative ROE and ROA metrics indicate shareholder capital is not yet being deployed productively to generate returns
- Heavy insider trading activity (25 Form 4 filings in 90 days) warrants monitoring for potential capital allocation concerns
- Sector is highly competitive and capital-intensive; sustained ability to convert gross margin to operating income not yet proven
- Operating margin remains meaningfully negative, showing the business has not reached durable earnings leverage
- Net income is still negative, so profitability improvement is not yet fully proven
- Cash generation could weaken if revenue growth slows or operating expenses remain elevated
Key Metrics to Watch
- Operating margin trajectory toward positive territory and path to EBITDA profitability
- Operating expense growth rate relative to revenue growth to demonstrate operating leverage
- Free cash flow sustainability and capex as percentage of revenue to assess reinvestment efficiency
- Gross margin stability to ensure pricing power and product mix remain favorable
- Operating margin trend
- Free cash flow consistency
Biolife Solutions Inc. (BLFS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.94x current ratio provides a solid financial cushion.
BLFS Profit Margin, ROE & Profitability Analysis
BLFS vs Healthcare Sector: How Biolife Solutions Inc. Compares
How Biolife Solutions Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biolife Solutions Inc. Stock Overvalued? BLFS Valuation Analysis 2026
Based on fundamental analysis, Biolife Solutions Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biolife Solutions Inc. Balance Sheet: BLFS Debt, Cash & Liquidity
BLFS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biolife Solutions Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
BLFS Revenue Growth, EPS Growth & YoY Performance
BLFS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $21.4M | $621.0K | $0.01 |
| Q2 2025 | $19.7M | -$15.8M | $-0.33 |
| Q1 2025 | $18.4M | -$448.0K | $-0.01 |
| Q3 2024 | $23.6M | -$1.7M | $-0.04 |
| Q2 2024 | $28.3M | -$10.2M | $-0.23 |
| Q1 2024 | $31.7M | -$10.2M | $-0.22 |
| Q3 2023 | $33.3M | -$10.3M | $-0.24 |
| Q2 2023 | $39.5M | -$10.2M | $-0.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biolife Solutions Inc. Dividends, Buybacks & Capital Allocation
BLFS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biolife Solutions Inc. (CIK: 0000834365)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775856566.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775856558.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/wk-form4_1775856548.xml | View → |
| Mar 31, 2026 | 4 | xslF345X06/wk-form4_1774991982.xml | View → |
| Mar 23, 2026 | 4 | xslF345X06/wk-form4_1774300146.xml | View → |
❓ Frequently Asked Questions about BLFS
What is the AI rating for BLFS?
Biolife Solutions Inc. (BLFS) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 67% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLFS's key strengths?
Claude: Strong revenue growth of 28.9% YoY indicates healthy market demand and successful commercial execution. Excellent gross margin of 64.6% demonstrates strong pricing power and cost management of core products. ChatGPT: Strong top-line growth supported by positive operating and free cash flow. High gross margin profile suggests attractive unit economics and pricing power.
What are the risks of investing in BLFS?
Claude: Significant operating loss of $16.6M with -17.3% operating margin indicates company is not yet at scale profitability. Operating cash flow of $20.1M only marginally exceeds capex of $9.5M, leaving limited buffer for growth investments. ChatGPT: Operating margin remains meaningfully negative, showing the business has not reached durable earnings leverage. Net income is still negative, so profitability improvement is not yet fully proven.
What is BLFS's revenue and growth?
Biolife Solutions Inc. reported revenue of $96.2M.
Does BLFS pay dividends?
Biolife Solutions Inc. does not currently pay dividends.
Where can I find BLFS SEC filings?
Official SEC filings for Biolife Solutions Inc. (CIK: 0000834365) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLFS's EPS?
Biolife Solutions Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BLFS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biolife Solutions Inc. has a BUY rating with 67% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BLFS stock overvalued or undervalued?
Valuation metrics for BLFS: ROE of -1.2% (sector avg: 15%), net margin of -4.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BLFS stock in 2026?
Our dual AI analysis gives Biolife Solutions Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BLFS's free cash flow?
Biolife Solutions Inc.'s operating cash flow is $20.1M, with capital expenditures of $9.5M. FCF margin is 11.1%.
How does BLFS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.8% (avg: 12%), ROE -1.2% (avg: 15%), current ratio 5.94 (avg: 2).